Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ribomic, Inc. ( (JP:4591) ) has provided an announcement.
Ribomic has filed a new substance patent application in Japan for RBM-006, a highly active anti-autotaxin aptamer with a shorter chain length than existing candidates, and reported that the molecule significantly suppressed retinal hemorrhage in a mouse model of diabetic retinopathy. The data, generated in collaboration with the University of Tokyo, strengthen the intellectual property position around RBM-006 and underscore its potential as a mechanistically distinct alternative to anti-VEGF drugs, which fail to benefit more than half of diabetic retinopathy patients, with the company planning to pursue early commercialization through partnerships while confirming that funding for development is secured and its full-year earnings forecast remains unchanged.
The most recent analyst rating on (JP:4591) stock is a Hold with a Yen84.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.
More about Ribomic, Inc.
Ribomic, Inc. (TYO:4591) is a clinical-stage pharmaceutical company specializing in aptamer therapeutics, focusing on developing novel treatments for ophthalmic diseases such as glaucoma, age-related macular degeneration and diabetic retinopathy. Leveraging its proprietary aptamer technology, the company aims to build a portfolio of eye disease drugs, with RBM-007 (umedaptanib pegol) as an existing core asset and the newly advanced anti-autotaxin aptamer RBM-006 positioned as a next flagship product.
Average Trading Volume: 937,991
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.56B
For an in-depth examination of 4591 stock, go to TipRanks’ Overview page.